Should I buy or sell Eisai stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ESALY shares. View ESALY analyst ratings or view top-rated stocks .

How have ESALY shares performed in 2024?

Eisai's stock was trading at $61.51 at the start of the year. Since then, ESALY shares have increased by 0.0% and is now trading at $61.51. View the best growth stocks for 2024 here .

How were Eisai's earnings last quarter?

Eisai Co., Ltd. (OTCMKTS:ESALY) issued its earnings results on Wednesday, August, 4th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm earned $1.82 billion during the quarter. Eisai had a net margin of 4.11% and a trailing twelve-month return on equity of 3.86%.

Is Eisai a good dividend stock?

Eisai (OTCMKTS:ESALY) pays an annual dividend of $0.88 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 101.15%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ESALY will have a dividend payout ratio of 73.95% next year. This indicates that the company will be able to sustain or increase its dividend.

How do I buy shares of Eisai?

Shares of ESALY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:ESALY

Eisai (ESALY) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free ESALY Stock Alerts

$61.51

-1.33 (-2.11%)

(As of 01/30/2023)

Compare

Today's Range: $61.00
▼
$63.29
50-Day Range: $61.51
▼
$61.51
52-Week Range: $36.88
▼
$73.90

Volume: 331,800 shs
Average Volume: 60,916 shs
Market Capitalization: $17.64 billion

P/E Ratio: 70.70
Dividend Yield: 1.43%
Price Target: N/A

Stock Analysis

Get Eisai alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Eisai Stock (OTCMKTS:ESALY)

Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.

ESALY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ESALY Stock News Headlines

April 13, 2024 | americanbankingnews.com

Eisai (OTCMKTS:ESALY) Stock Price Crosses Below 50-Day Moving Average of $61.51

March 29, 2024 | wsj.com

Eisai Co. Ltd. ADR

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 23, 2024 | reuters.com

Eisai Co Ltd

March 20, 2024 | morningstar.com

Eisai Co Ltd 4523

February 15, 2024 | finance.yahoo.com

BIIB Mar 2024 210.000 call

February 15, 2024 | finance.yahoo.com

BIIB Mar 2024 235.000 call

February 15, 2024 | finance.yahoo.com

BIIB Feb 2024 227.500 call

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 14, 2024 | finance.yahoo.com

BIIB Mar 2024 205.000 put

January 12, 2024 | seekingalpha.com

ESALF Eisai Co., Ltd.

December 8, 2023 | markets.businessinsider.com

Merck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet Endpoints

September 25, 2023 | msn.com

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi

September 22, 2023 | msn.com

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer

July 6, 2023 | markets.businessinsider.com

FDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's Disease

June 13, 2023 | benzinga.com

Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources

June 11, 2023 | markets.businessinsider.com

FDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug Leqembi

June 8, 2023 | msn.com

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'

January 9, 2023 | finance.yahoo.com

UTHR or ESALY: Which Is the Better Value Stock Right Now?

January 6, 2023 | finance.yahoo.com

FDA approves treatment for people with mild forms of Alzheimer’s

November 30, 2022 | finance.yahoo.com

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate

November 30, 2022 | seekingalpha.com

Biogen rallies Alzheimer’s drug developers after full data for lecanemab

November 30, 2022 | finance.yahoo.com

Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's

November 30, 2022 | seekingalpha.com

Biogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swelling

November 30, 2022 | barrons.com

Biogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.

November 28, 2022 | seekingalpha.com

Biogen drops after report on second death linked to Alzheimer’s candidate

November 28, 2022 | finance.yahoo.com

UTHR vs. ESALY: Which Stock Is the Better Value Option?

See More Headlines

Receive ESALY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/04/2021
Today: 4/19/2024
Fiscal Year End: 3/31/2025

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Private households
Sub-Industry: N/A
Current Symbol: OTCMKTS:ESALY
CUSIP: N/A
CIK: 948406
Web: www.eisai.co.jp
Phone: (133) 817-3700
Fax: 813-3811-6032
Employees: 11,322
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.87
Trailing P/E Ratio: 70.70
Forward P/E Ratio: 32.37
P/E Growth: 2.46
Net Income: $426.79 million
Net Margins: 4.11%
Pretax Margin: N/A
Return on Equity: 3.86%
Return on Assets: 2.50%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 2.20
Quick Ratio: 1.77

Sales & Book Value

Annual Sales: $6.74 billion
Price / Sales: 2.62
Cash Flow: $2.68 per share
Price / Cash Flow: 22.94
Book Value: $23.94 per share
Price / Book: 2.57

Miscellaneous

Outstanding Shares: 286,770,000
Free Float: N/A
Market Cap: $17.64 billion
Optionable: Not Optionable
Beta: 0.31

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Haruo Naito
Chief Executive Officer & Director
Yasushi Okada
COO, Representative Executive Officer & Head-China
Tatsuyuki Yasuno
Chief Financial & investor Relations Officer
Keisuke Naito
Executive Officer & Head-Global IT Headquarters
Yosuke Akita
Chief Compliance Officer & & Head-Internal Control

Key Competitors

View All Competitors

Should I Buy Eisai Stock? ESALY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Eisai Co., Ltd.:

Eisai Co., Ltd. recently inked a $2 billion oncology deal with a China-based startup, indicating strategic expansion and potential growth opportunities in the oncology sector.
The company operates in the pharmaceutical industry, focusing on prescription medicines and over-the-counter products, which are essential for healthcare and have a steady demand.
Eisai Co., Ltd. has a long-standing history since its founding in 1936, showcasing stability and experience in the market.
With a diverse portfolio that includes prescription drugs, diagnostics, consumer healthcare products, food additives, and chemicals, Eisai Co., Ltd. has multiple revenue streams that can mitigate risks.
Investors may find Eisai Co., Ltd. stock attractive based on its current price and potential for growth in the pharmaceutical market.

Cons

Investors should be bearish about investing in Eisai Co., Ltd. for these reasons:

Market competition in the pharmaceutical industry is intense, which could impact Eisai Co., Ltd.'s market share and profitability.
Regulatory challenges and changes in healthcare policies can affect the company's operations and financial performance.
Fluctuations in currency exchange rates may pose risks to Eisai Co., Ltd.'s international business operations and revenue.
Dependency on a few key products or markets could expose the company to risks if there are disruptions in those areas.
Economic uncertainties and global health crises can impact the demand for pharmaceutical products, affecting Eisai Co., Ltd.'s sales and revenue.

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Eisai pros and cons to contact@marketbeat.com.

ESALY Stock Analysis - Frequently Asked Questions

Should I buy or sell Eisai stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ESALY shares.
View ESALY analyst ratings or view top-rated stocks.
How have ESALY shares performed in 2024?: Eisai's stock was trading at $61.51 at the start of the year. Since then, ESALY shares have increased by 0.0% and is now trading at $61.51.
View the best growth stocks for 2024 here.
How were Eisai's earnings last quarter?: Eisai Co., Ltd. (OTCMKTS:ESALY) issued its earnings results on Wednesday, August, 4th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm earned $1.82 billion during the quarter. Eisai had a net margin of 4.11% and a trailing twelve-month return on equity of 3.86%.

Is Eisai a good dividend stock?: Eisai (OTCMKTS:ESALY) pays an annual dividend of $0.88 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 101.15%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ESALY will have a dividend payout ratio of 73.95% next year. This indicates that the company will be able to sustain or increase its dividend.
How do I buy shares of Eisai?: Shares of ESALY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:ESALY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eisai (ESALY) Stock Price, News & Analysis

About Eisai Stock (OTCMKTS:ESALY)

ESALY Stock Price History

ESALY Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Should I Buy Eisai Stock? ESALY Pros and Cons Explained

Pros

Cons

ESALY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info